These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 30488021)

  • 21. Transarterial chemoembolization for hepatocellular carcinoma: 2023 expert consensus-based practical recommendations of the Korean Liver Cancer Association.
    Cho Y; Choi JW; Kwon H; Kim KY; Lee BC; Chu HH; Lee DH; Lee HA; Kim GM; Oh JS; Hyun D; Lee IJ; Rhim H;
    J Liver Cancer; 2023 Sep; 23(2):241-261. PubMed ID: 37449302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
    BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
    Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
    BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence.
    Raoul JL; Forner A; Bolondi L; Cheung TT; Kloeckner R; de Baere T
    Cancer Treat Rev; 2019 Jan; 72():28-36. PubMed ID: 30447470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Huang K; Zhou Q; Wang R; Cheng D; Ma Y
    J Gastroenterol Hepatol; 2014 May; 29(5):920-5. PubMed ID: 24224722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transarterial chemoembolization (TACE) in the management of hepatocellular carcinoma: Results of a French national survey on current practices.
    Fohlen A; Tasu JP; Kobeiter H; Bartoli JM; Pelage JP; Guiu B
    Diagn Interv Imaging; 2018 Sep; 99(9):527-535. PubMed ID: 29609903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art.
    Facciorusso A
    World J Gastroenterol; 2018 Jan; 24(2):161-169. PubMed ID: 29375202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sulfamethazine-based pH-sensitive hydrogels with potential application for transcatheter arterial chemoembolization therapy.
    Lym JS; Nguyen QV; Ahn da W; Huynh CT; Jae HJ; Kim YI; Lee DS
    Acta Biomater; 2016 Sep; 41():253-63. PubMed ID: 27184404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma.
    Malagari K; Pomoni M; Kelekis A; Pomoni A; Dourakis S; Spyridopoulos T; Moschouris H; Emmanouil E; Rizos S; Kelekis D
    Cardiovasc Intervent Radiol; 2010 Jun; 33(3):541-51. PubMed ID: 19937027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
    Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma: a meta-analysis.
    Ni JY; Xu LF; Wang WD; Sun HL; Chen YT
    World J Gastroenterol; 2014 Dec; 20(45):17206-17. PubMed ID: 25493037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma].
    Ferrer Puchol MD; la Parra C; Esteban E; Vaño M; Forment M; Vera A; Cosín O
    Radiologia; 2011; 53(3):246-53. PubMed ID: 21295802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma.
    Hatanaka T; Arai H; Kakizaki S
    World J Hepatol; 2018 Jul; 10(7):485-495. PubMed ID: 30079135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transarterial chemoembolization for hepatocellular carcinoma: A review of techniques.
    Imai N; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Hayashi K; Hirooka Y; Goto H
    World J Hepatol; 2014 Dec; 6(12):844-50. PubMed ID: 25544871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surgical and Locoregional Therapy of HCC: TACE.
    Tsurusaki M; Murakami T
    Liver Cancer; 2015 Sep; 4(3):165-75. PubMed ID: 26675172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
    Wu B; Zhou J; Ling G; Zhu D; Long Q
    World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conventional
    Song JE; Kim DY
    World J Hepatol; 2017 Jun; 9(18):808-814. PubMed ID: 28706579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is radioembolization ((90)Y) better than doxorubicin drug eluting beads (DEBDOX) for hepatocellular carcinoma with portal vein thrombosis? A retrospective analysis.
    Akinwande O; Kim D; Edwards J; Brown R; Philips P; Scoggins C; Martin RC
    Surg Oncol; 2015 Sep; 24(3):270-5. PubMed ID: 26133576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In Vivo Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinoma.
    Lilienberg E; Dubbelboer IR; Karalli A; Axelsson R; Brismar TB; Ebeling Barbier C; Norén A; Duraj F; Hedeland M; Bondesson U; Sjögren E; Stål P; Nyman R; Lennernäs H
    Mol Pharm; 2017 Feb; 14(2):448-458. PubMed ID: 27997198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization.
    Lewis AL; Gonzalez MV; Lloyd AW; Hall B; Tang Y; Willis SL; Leppard SW; Wolfenden LC; Palmer RR; Stratford PW
    J Vasc Interv Radiol; 2006 Feb; 17(2 Pt 1):335-42. PubMed ID: 16517780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.